Nurix Therapeutics, Inc. (NRIX) — Financial statements
Income statement, balance sheet, and cash flow for Nurix Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 84↑54.0% | 55↓29.1% | 77↑99.3% | 39↑29.8% | 30 | |
| Cost of Revenue | 19↓91.5% | 222↑17.2% | 189↑2.5% | 184↑58.5% | 116 | |
| Gross Profit | 65↑139.0% | -167↓49.0% | -112↑23.1% | -146↓68.3% | -87 | |
| Operating Expenses | ||||||
| R&D Expenses | 308↑39.0% | 222↑17.2% | 189↑2.5% | 184↑58.5% | 116 | |
| General & Administrative Expenses | 53↑14.8% | 46↑7.1% | 43↑12.9% | 38↑21.8% | 31 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 53↑14.8% | 46↑7.1% | 43↑12.9% | 38↑21.8% | 31 | |
| Other Expenses | -10↑95.4% | -222↓17.2% | -189↓2.5% | -184↓58.5% | -116 | |
| Operating Expenses | 351↑663.5% | 46↑7.1% | 43↑12.9% | 38↑21.8% | 31 | |
| Total Costs & Expenses | 370↑38.1% | 268↑15.3% | 232↑4.3% | 222↑50.7% | 148 | |
| Operating Results | ||||||
| Operating Income | -286↓34.1% | -213↓37.4% | -155↑15.7% | -184↓56.0% | -118 | |
| Depreciation & Amortization | 19↑135.2% | 8↑30.7% | 6↑47.8% | 4↑108.5% | 2 | |
| EBITDA | -245↓19.4% | -205↓37.7% | -149↑17.1% | -180↓55.1% | -116 | |
| EBIT | -264↓23.8% | -213↓37.4% | -155↑15.7% | -184↓56.0% | -118 | |
| Interest & Other Income | ||||||
| Net Interest Income | 22↑11.4% | 20↑77.5% | 11↑216.9% | 4↑326.1% | 0.82 | |
| Interest Income | 22↑11.4% | 20↑77.5% | 11↑216.9% | 4↑326.1% | 0.82 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -22 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 22↑11.4% | 20↑77.5% | 11↑216.9% | 4↑326.1% | 0.82 | |
| Income Before Tax | -264↓36.4% | -193↓34.3% | -144↑20.2% | -180↓54.1% | -117 | |
| Income Tax Expense | 0.76↑181.5% | 0.27 | 0.00 | 0.00↓100.0% | 0.13 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -264↓36.6% | -194↓34.5% | -144↑20.2% | -180↓53.9% | -117 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -264↓36.6% | -194↓34.5% | -144↑20.2% | -180↓53.9% | -117 | |
| Bottom-Line Net Income | -264↓36.6% | -194↓34.5% | -144↑20.2% | -180↓53.9% | -117 | |
| EPS (Basic) | -3.05↓5.9% | -2.88↓8.7% | -2.65↑28.6% | -3.71↓35.9% | -2.73 | |
| EPS (Diluted) | -3.05↓5.9% | -2.88↓8.7% | -2.65↑28.6% | -3.71↓35.9% | -2.73 | |
| Weighted Average Shares | 87↑29.1% | 67↑23.5% | 54↑11.8% | 49↑13.3% | 43 | |
| Weighted Average Diluted Shares | 87↑29.1% | 67↑23.5% | 54↑11.8% | 49↑13.3% | 43 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.